Sarepta Therapeutics Inc $24.23

up +1.56


16/4/2014 08:10 PM  |  NASDAQ : SRPT  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get SRPT Trend Analysis - it has underperformed the S&P 500 by 47%

Partner Headlines

  1. Prosensa Muscular Dystrophy Data Send Stock Rising

    IBD
  2. Benzinga's Top #PreMarket Losers

    Benzinga
  3. UPDATE: Sarepta Announces Positive Safety Results from Phase I Trial of ...

    Benzinga
  4. UPDATE: JMP Downgrades Sarepta, Data Considered Weak and Overstated

    Benzinga
  5. Needham Upgrades Sarepta, Says Stock Underalued Even In Conservative Case

    Benzinga
  6. Is The Market On Drugs?

    Benzinga
  7. Mid-Morning Market Update: Markets Mostly Lower; Goldman Sachs Posts Upbeat ...

    Benzinga
  8. Morning Market Movers

    Benzinga
  9. Benzinga's Top #PreMarket Gainers

    Benzinga
  10. UPDATE: Sarepta Downgraded by Citigroup on Eteplirsen Early Approval Setback

    Benzinga
  11. Mid-Morning Market Update: Markets Mostly Lower; GE To Acquire Thermo Fisher ...

    Benzinga
  12. Morning Market Losers

    Benzinga
  13. Benzinga's Top #PreMarket Losers

    Benzinga
  14. UPDATE: Canaccord Genuity Downgrades Sarepta Therapeutics as FDA Talks ...

    Benzinga
  15. Market Wrap For November 26: Nasdaq Closes Above 4,000 For First Time Since ...

    Benzinga
  16. Mid-Afternoon Market Update: Markets Rise as NASDAQ Eyes Close Over 4, ...

    Benzinga
  17. UPDATE: Deutsche Bank Downgrades Sarepta Therapeutics Following FDA Announcement ...

    Benzinga
  18. Sarepta Plunges And Love Affair Ends (For Now)

    YCharts
  19. Sarepta sinks on FDA report

    IBD
  20. Market Wrap For November 12: Investors Continue to Speculate on the Fed's ...

    Benzinga
  21. Mid-Afternoon Market Update: Markets in the Red as American Airlines/US ...

    Benzinga
  22. Sarepta Therapeutics Plunges On Negative FDA Report

    IBD
  23. UPDATE: Piper Jaffray Downgrades Sarepta Therapeutics After FDA Reverses ...

    Benzinga
  24. Benzinga's Top #PreMarket Losers

    Benzinga
  25. Sarepta Therapeutics Announces FDA Considers NDA Filing for Eteplirsen ...

    Benzinga
  26. PPMD, Sarepta Report Program for Genetic Testing at No Cost

    Benzinga
  27. Insiders Are Buying Fate Therapeutics

    GuruFocus
  28. Sarepta Takes The Lead In Muscular Dystrophy Race

    IBD
  29. Sarepta Says Eteplirsen Showed Continued Stability on Walking Test Through ...

    Benzinga
  30. Prosensa falls on test fail

    IBD
  31. Market Wrap For Friday, September 20: Market Gives Up Bernanke's Boost

    Benzinga
  32. UPDATE: Deutsche Bank Upgraded, Raised Target on Sarepta, No Competition ...

    Benzinga
  33. Mid-Afternoon Market Update: BlackBerry Releases Awful Guidance, Proves ...

    Benzinga
  34. Mid-Day Market Update: US Stocks Drop; TIBCO Shares Surge On Upbeat Results

    Benzinga
  35. Prosensa Plunges, Sarepta Dithers As DMD Drug Fails

    IBD
  36. Benzinga's Top Pre-Market Losers

    Benzinga
  37. UPDATE: Stifel Initiates Coverage on Sarepta Therapeutics on Attractive ...

    Benzinga
  38. Benzinga's Top Pre-Market Gainers

    Benzinga
  39. Market Wrap For Monday, August 12: Stocks Close Mixed To Start Week

    Benzinga
  40. Mid-Afternoon Market Update: Silver Continues Strong Rally as Sarepta Remains ...

    Benzinga
  41. Sarepta Therapeutics Announces Publication of Eteplirsen Clinical Study ...

    Benzinga
  42. Sarepta Therapeutics Drops on Fake Citron Tweet

    Benzinga
  43. UPDATE: Piper Jaffray Cuts PT to $35 on Sarepta Therapeutics on Share Dilution; ...

    Benzinga
  44. The Best Small Cap Performers of 2012

    Benzinga
  45. UPDATE: Piper Jaffray Reiterates Sarepta Therapeutics at Buy on Positive ...

    Benzinga
  46. BioMarin, Prestige Brands and Other Top Performing Health Care Stocks in ...

    Benzinga
  47. Benzinga's M&A Chatter for Wednesday November 28, 2012

    Benzinga
  48. UPDATE: Burril Initiates Sarepta Therapeutics at Market Outperform on Eteplirsen ...

    Benzinga
  49. Sarepta Announces Collaboration for Development of Added Exon-Skipping ...

    Benzinga
  50. Mid-Morning Market Update: Markets Largely Flat; Hostess to Continue With ...

    Benzinga
Trading Center